Medicus Pharma Ltd. Common Stock

Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI

Medicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progresses

Medicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-Pacific

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Medicus Pharma makes debut on Nasdaq raising $4M to advance skin cancer trial - ICYMI

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Medicus Pharma announces pricing of US IPO

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

Medicus Pharma Ltd. Announces Share Consolidation in Anticipation of Proposed U.S. Listing

Medicus Pharma Ltd. Announces First Patient Randomized in Phase 2 Trial of SKNJCT-003 for the Treatment of Nodular Basal Cell Carcinoma in Adults

Medicus Pharma Ltd. Submits Updated Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin

Medicus Pharma Ltd. Announces Closing of Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes

Medicus Pharma Ltd. Announces Proposed Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes

Medicus Pharma Ltd. Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States